Search the Newsreel

What Does IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Share Price Indicate?

This article analyzes IDEXX Laboratories, Inc.'s stock price movements and valuation, utilizing a discounted cash flow (DCF) model to estimate its intrinsic value. It suggests the stock may be trading below its fair value, indicating potential for growth despite a recent price decline.

IDEXX Laboratories Inc (IDXX) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Projeções de Resultados: IDEXX Laboratories Inc (IDXX) — LPA e Crescimento de Receita

Royal Bank of Canada Decreases Position in IDEX Corporation $IEX

Royal Bank of Canada reduced its stake in IDEX Corporation by 6.9% in the first quarter of 2026, selling 6,645 shares and retaining 89,664 shares valued at $17 million. Despite this reduction, institutional investors collectively own 97.96% of IDEX. The company reported strong quarterly …

Clinical Visits Keep Falling. IDEXX Laboratories’ Q2 Earnings Report Say That Doesn’t Matter.

D.A. Davidson Maintains IDEX Corp(IEX.US) With Hold Rating, Raises Target Price to $240

D.A. Davidson has reiterated a Hold rating on IDEX Corp (IEX.US) while increasing its price target to $240. This adjustment reflects the firm's updated valuation for the company.

IDEX Corp. stock underperforms Thursday when compared to competitors

IDEX Corp. (IEX) stock fell 1.38% on Thursday, closing at $233.71, underperforming the broader market. This marked the second consecutive day of losses for the company, as the S&P 500 Index (SPX) also declined by 0.18% and the Dow Jones Industrial Average (DJIA) fell …

Are You Looking for a Top Momentum Pick? Why Idex (IEX) is a Great Choice

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of …

How IDEXX’s Raised 2026 Earnings Outlook Will Impact IDEXX Laboratories (IDXX) Investors

IDEXX Labs Is Maintained at Neutral by UBS

UBS has maintained its "Neutral" rating on IDEXX Labs (IDXX) stock. This indicates that the analyst believes the stock will perform in line with the market. No specific financial data or price targets were provided in this brief announcement.

IDEX CORPORATION : ARGUS RESEARCH RAISES TARGET PRICE TO $260 FROM $250

Argus Research has increased its target price for IDEX Corporation (IEX.N) to $260 from $250. This update was reported by Reuters on August 6, 2026. The article itself is a brief news alert, providing no further details on the rationale behind the target price …

IDEXX Laboratories 2026: Revenue $1.22B, EPS $4.27— 10-Q Summary

IDEXX Laboratories reported strong financial results for the quarter ended 2026, with revenue of $1.22 billion and diluted EPS of $4.27, both exceeding the prior year. The growth was driven by higher volumes and prices in core segments, particularly recurring diagnostics and reference lab …

Iridex schedules Q2 business update after Aug. 18 close

Iridex (Nasdaq: IRIX) announced it will release its second quarter 2026 financial results and provide a business update after the market close on August 18, 2026. The company's management will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss …

Jefferies Adjusts Price Target on IDEXX Laboratories to $795 From $792

Jefferies has increased its price target for IDEXX Laboratories (IDXX) to $795 from the previous $792, while maintaining a Hold rating on the stock. This adjustment reflects a modest change in the firm's outlook for the company.

Citigroup Adjusts Price Target on IDEXX Laboratories to $670 From $650

Citigroup has raised its price target for IDEXX Laboratories (IDXX) from $650 to $670, as reported on August 5, 2026. This adjustment follows other recent analyst updates for the company, including Jefferies increasing its target to $795 and UBS raising its target to $670. …

UBS Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Raises Target Price to $670

UBS has reiterated its Hold rating on IDEXX Laboratories Inc (IDXX.US) and increased its price target to $670. This adjustment reflects the firm's updated valuation for the company.

Janus Henderson Group PLC Has $15.44 Million Stock Holdings in IDEX Corporation $IEX

Janus Henderson Group PLC significantly increased its stake in IDEX Corporation (NYSE:IEX) by 953.1% in the first quarter, now holding 81,444 shares valued at $15.44 million. Other institutional investors also adjusted their positions, and insider Eric D. Ashleman sold over 15,000 shares in May. …

IDEX Corporation $IEX Shares Purchased by Bank of America Corp DE

Bank of America Corp DE significantly increased its stake in IDEX Corporation, purchasing an additional 746,732 shares, bringing its total holding to 1,094,101 shares valued at approximately $207.4 million. Other institutional investors also adjusted their positions in IDEX, with a total of 97.96% of …

IDEXX Laboratories, Inc. Stock 12‑Month Price Target Raised to $719, Implies 27% Upside

Analysts have raised the average 12-month price target for IDEXX Laboratories, Inc. (IDXX) stock to $719, up from $711.64, with a range between $620 and $805. This new target suggests a potential upside of approximately 27% from its Aug. 3 closing price. The consensus …

IDEXX (IDXX) Stock Rewards Margin Strength And Recurring Diagnostics Growth

William Blair Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating

William Blair has reiterated its Buy rating on IDEXX Laboratories Inc (IDXX.US). This continued endorsement reflects a positive outlook from the firm regarding the company's performance and prospects.

IDEXX Laboratories (NASDAQ: IDXX) lifts Q2 2026 profit and cash flow

IDEXX Laboratories jumps 5% on strong results, raised guidance (IDXX:NASDAQ)

IDEXX Laboratories (IDXX) shares rose over 5% after the company reported strong second-quarter results and provided upbeat full-year earnings guidance. The veterinary diagnostics company posted an adjusted EPS of $4.07 for the quarter. This positive performance has led to a significant increase in its …

Iridex to Report Second Quarter 2026 Financial Results on August 18, 2026

Iridex Corporation (Nasdaq: IRIX) announced it will release its second quarter 2026 financial results and provide a business update on August 18, 2026, after the close of trading. The company's management team will host a conference call at 2:00 p.m. PT / 5:00 p.m. …

IDEXX Laboratories Q2 2026 Earnings Call Transcript

IDEXX Laboratories reported strong Q2 2026 financial results, with a 10% revenue increase and a raised full-year outlook. The company highlighted robust growth in CAG Diagnostics, Water, and LPD businesses, driven by innovation, increased diagnostic utilization, and expanding customer

IDEXX Laboratories Announces Second Quarter Results

IDEXX Laboratories reported strong second quarter 2026 results, with revenue growth of 10% and EPS increasing by 18%. The company's Companion Animal Group Diagnostics recurring revenue grew by 11%, driven by innovation and increased diagnostic utilization. IDEXX also narrowed its 2026 revenue guidance and …

Idexx Laboratories (IDXX) Q2 Earnings and Revenues Top Estimates

Idexx Laboratories (IDXX) reported strong Q2 2026 earnings, beating Zacks Consensus Estimates for both earnings per share ($4.27 vs. $3.95) and revenues ($1.22 billion vs. $1.20 billion). The company has consistently surpassed analyst expectations over the past four quarters. Despite the positive results, Idexx …

IDEXX Labs earnings beat by $0.31, revenue topped estimates

IDEXX Labs (NASDAQ: IDXX) reported strong Q2 results, with EPS of $4.27 surpassing analyst estimates by $0.31 and revenue reaching $1.22 billion, exceeding the consensus. The company also provided optimistic FY 2026 guidance, projecting EPS between $14.69 and $14.94 and revenue of $4.70 billion …

Earnings Flash (IDXX) IDEXX Laboratories Posts Q2 Adjusted EPS $4.07, vs. FactSet Est of $3.94

IDEXX Laboratories (IDXX) announced its Q2 adjusted earnings per share (EPS) of $4.07, surpassing the FactSet estimate of $3.94. The company also reported increased Q2 comparable earnings and revenue, and provided an updated 2026 outlook. IDEXX Laboratories is a global leader in diagnostic instruments …

Earnings Flash (IDXX) IDEXX Laboratories, Inc. Reports Q2 Revenue $1.22B, vs. FactSet Est of $1.20B

IDEXX Laboratories, Inc. (IDXX) reported strong second-quarter results, with revenue reaching $1.22 billion, surpassing FactSet's estimate of $1.20 billion. The company also announced adjusted EPS of $4.07, exceeding the FactSet estimate of $3.94. This positive earnings flash highlights IDEXX's continued growth in the medical …

IDEXX Labs stock rises nearly 4% on earnings beat and raised guidance

IDEXX Laboratories Inc. reported strong second-quarter results, exceeding analyst expectations for both adjusted EPS and revenue. The company also raised its full-year 2026 EPS guidance, leading to a nearly 4% rise in its stock during pre-market trading. Key drivers included the "Technology for Life" …

IDEXX Laboratories, Inc. (NASDAQ: IDXX) lifts 2026 outlook after strong Q2

Idexx (IDXX) Reports Q2 Earnings: What Key Metrics Have to Say

Update: IDEXX Laboratories' Q2 Earnings, Revenue Increase; 2026 Outlook Updated

IDXX Q2 Earnings & Revenues Beat, '26 EPS View Up, Stock Up in Pre-Market

IDEXX Laboratories Shares Climb After Earnings Beat and Improved Full-Year Outlook